The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Effects of Interleukin-1 Blockade With Anakinra on Adverse Cardiac Remodeling and Heart Failure After Acute Myocardial Infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) Pilot Study]
Open accessAbstract
Acute myocardial infarction (AMI) initiates an intense inflammatory response in which interleukin-1 (IL-1) plays a central role. The IL-1 receptor antagonist is a naturally occurring antagonist, and anakinra is the recombinant form used to treat inflammatory diseases. The aim of the present pilot study was to test the safety and effects of IL-1 blockade with anakinra on left ventricular (LV) remodeling after AMI. Ten patients with ST-segment elevation AMI were randomized to either anakinra 100 mg/day subcutaneously for 14 days or placebo in a double-blind fashion. Two cardiac magnetic resonance (CMR) imaging and echocardiographic studies were performed during a 10- to 14-week period. The primary end point was the difference in the interval change in the LV end-systolic volume index (LVESVi) between the 2 groups on CMR imaging. The secondary end points included differences in the interval changes in the LV end-diastolic volume index, and C-reactive protein levels. A +2.0 ml/m2 median increase (interquartile range +1.0, +11.5) in the LVESVi on CMR imaging was seen in the placebo group and a –3.2 ml/m2 median decrease (interquartile range –4.5, –1.6) was seen in the anakinra group (p = 0.033). The median difference was 5.2 ml/m2. On echocardiography, the median difference in the LVESVi change was 13.4 ml/m2 (p = 0.006). Similar differences were observed in the LV end-diastolic volume index on CMR imaging (7.6 ml/m2, p = 0.033) and echocardiography (9.4 ml/m2, p = 0.008). The change in C-reactive protein levels between admission and 72 hours after admission correlated with the change in the LVESVi (R =+0.71, p = 0.022). In conclusion, in the present pilot study of patients with ST-segment elevation AMI, IL-1 blockade with anakinra was safe and favorably affected by LV remodeling. If confirmed in larger trials, IL-1 blockade might represent a novel therapeutic strategy to prevent heart failure after AMI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., et al. (2003) · Circulation · doi:10.1161/01.cir.0000052939.59093.45 · Cited by 6,401
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Writing Group Members, Rosamond, W., Flegal, K., Furie, K., Go, A., Greenlund, K., Haase, N., Hailpern, S. M., Ho, M., Howard, V., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.187998 · Cited by 3,711
Immunological and inflammatory functions of the interleukin-1 family
Dinarello, C. A. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132612 · Cited by 3,466
Self-citationWhite, H. D., Norris, R. M., Brown, M. A., Brandt, P. W., Whitlock, R. M., & Wild, C. J. (1987) · Circulation · doi:10.1161/01.cir.76.1.44 · Cited by 2,363
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
Dinarello, C. A. (2011) · Blood · doi:10.1182/blood-2010-07-273417 · Cited by 2,248
Self-citationTreating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,768
Self-citationMorrow, D. A., Antman, E. M., Charlesworth, A., Cairns, R., Murphy, S. A., de Lemos, J. A., Giugliano, R. P., McCabe, C. H., & Braunwald, E. (2000) · Circulation · doi:10.1161/01.cir.102.17.2031 · Cited by 1,558
Cardiovascular Medicine at the Turn of the Millennium: Triumphs, Concerns, and Opportunities
Braunwald, E. (1997) · New England Journal of Medicine · doi:10.1056/nejm199711063371906 · Cited by 1,424
Regulation of the Inflammatory Response in Cardiac Repair
Frangogiannis, N. G. (2012) · Circulation Research · doi:10.1161/circresaha.111.243162 · Cited by 1,194
Effect of Captopril on Progressive Ventricular Dilatation after Anterior Myocardial Infarction
Pfeffer, M. A., Lamas, G. A., Vaughan, D. E., Parisi, A. F., & Braunwald, E. (1988) · New England Journal of Medicine · doi:10.1056/nejm198807143190204 · Cited by 1,103
St John Sutton, M., Pfeffer, M. A., Plappert, T., Rouleau, J. L., Moyé, L. A., Dagenais, G. R., Lamas, G. A., Klein, M., Sussex, B., & Goldman, S. (1994) · Circulation · doi:10.1161/01.cir.89.1.68 · Cited by 823
The immune system and cardiac repair
FRANGOGIANNIS, N. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.06.007 · Cited by 641
Mezzaroma, E., Toldo, S., Farkas, D., Seropian, I. M., Van Tassell, B. W., Salloum, F. N., Kannan, H. R., Menna, A. C., Voelkel, N. F., & Abbate, A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108586108 · Cited by 629
Self-citationBiasucci, L. M., Liuzzo, G., Grillo, R. L., Caligiuri, G., Rebuzzi, A. G., Buffon, A., Summaria, F., Ginnetti, F., Fadda, G., & Maseri, A. (1999) · Circulation · doi:10.1161/01.cir.99.7.855 · Cited by 582
Long-Term Trends in the Incidence of Heart Failure After Myocardial Infarction
Velagaleti, R. S., Pencina, M. J., Murabito, J. M., Wang, T. J., Parikh, N. I., D'Agostino, R. B., Levy, D., Kannel, W. B., & Vasan, R. S. (2008) · Circulation · doi:10.1161/circulationaha.108.784215 · Cited by 535
Abbate, A., Kontos, M. C., Grizzard, J. D., Biondi-Zoccai, G. G. L., Van Tassell, B. W., Robati, R., Roach, L. M., Arena, R. A., Roberts, C. S., Varma, A., et al. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.12.059 · Cited by 415
Self-citationInterleukin-1 Receptor Type I Signaling Critically Regulates Infarct Healing and Cardiac Remodeling
Bujak, M., Dobaczewski, M., Chatila, K., Mendoza, L. H., Li, N., Reddy, A., & Frangogiannis, N. G. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.070974 · Cited by 365
Abbate, A., Salloum, F. N., Vecile, E., Das, A., Hoke, N. N., Straino, S., Biondi-Zoccai, G. G. L., Houser, J.-E., Qureshi, I. Z., Ownby, E. D., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.740233 · Cited by 360
Self-citationGardin, J. M., Adams, D. B., Douglas, P. S., Feigenbaum, H., Forst, D. H., Fraser, A. G., Grayburn, P. A., Katz, A. S., Keller, A. M., Kerber, R. E., et al. (2002) · Journal of the American Society of Echocardiography · doi:10.1067/mje.2002.121536 · Cited by 348
Doughty, R. N., Whalley, G. A., Walsh, H. A., Gamble, G. D., López-Sendón, J., & Sharpe, N. (2004) · Circulation · doi:10.1161/01.cir.0000108928.25690.94 · Cited by 328
Pomerantz, B. J., Reznikov, L. L., Harken, A. H., & Dinarello, C. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.041611398 · Cited by 310
Self-citationThe role of IL-1 in the pathogenesis of heart disease
Bujak, M., & Frangogiannis, N. G. (2009) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-009-0024-y · Cited by 307
Ikonomidis, I., Lekakis, J. P., Nikolaou, M., Paraskevaidis, I., Andreadou, I., Kaplanoglou, T., Katsimbri, P., Skarantavos, G., Soucacos, P. N., & Kremastinos, D. T. (2008) · Circulation · doi:10.1161/circulationaha.107.731877 · Cited by 307
Suzuki, K., Murtuza, B., Smolenski, R. T., Sammut, I. A., Suzuki, N., Kaneda, Y., & Yacoub, M. H. (2001) · Circulation · doi:10.1161/hc37t1.094871 · Cited by 202
Furst, D. E. (2004) · Clinical Therapeutics · doi:10.1016/j.clinthera.2004.12.019 · Cited by 171
Orn, S., Manhenke, C., Ueland, T., Damas, J. K., Mollnes, T. E., Edvardsen, T., Aukrust, P., & Dickstein, K. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp070 · Cited by 170
Surrogate end points in heart failure
Anand, I. S., Florea, V. G., & Fisher, L. D. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)01773-4 · Cited by 153
Kaplanski, G., Porat, R., Aiura, K., Erban, J., Gelfand, J. A., & Dinarello, C. A. (1993) · Blood · doi:10.1182/blood.v81.10.2492.2492 · Cited by 147
Self-citationAbbate, A., Tassell, B. W. V., Seropian, I. M., Toldo, S. A., Robati, R., Varma, A., Salloum, F. N., Smithson, L. A., & Dinarello, C. A. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq017 · Cited by 113
Self-citationGoldberg, R. J., Spencer, F. A., Yarzebski, J., Lessard, D., Gore, J. M., Alpert, J. S., & Dalen, J. E. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.07.142 · Cited by 90
Tassell, B. W. V., Varma, A., Salloum, F. N., Das, A., Seropian, I. M., Toldo, S. A., Smithson, L. A., Hoke, N. N., Chau, V. Q., Robati, R., et al. (2010) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3181c87e53 · Cited by 84
Self-citationAbbate, A., Tassell, B. W. V., & Biondi‐Zoccai, G. (2012) · BioDrugs · doi:10.1007/bf03261881 · Cited by 84
Self-citationCrossman, D. C., Morton, A. C., Gunn, J. P., Greenwood, J. P., Hall, A. S., Fox, K. A. A., Lucking, A. J., Flather, M. D., Lees, B., & Foley, C. E. (2008) · Trials · doi:10.1186/1745-6215-9-8 · Cited by 81
Left ventricular remodeling after acute myocardial infarction: Does eplerenone have an effect?
Weir, R. A. P., Mark, P. B., Petrie, C. J., Clements, S. E., Steedman, T., Ford, I., Ng, L. L., Squire, I. B., Wagner, G. S., McMurray, J. J. V., et al. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.04.001 · Cited by 68
Saraste, A., Nekolla, S. G., & Schwaiger, M. (2008) · Journal of Nuclear Cardiology · doi:10.1007/bf02976902 · Cited by 47
Cited by
Overview of the IL ‐1 family in innate inflammation and acquired immunity
Dinarello, C. A. (2018) · Immunological Reviews · doi:10.1111/imr.12621 · Cited by 1,866
Self-citationThe inflammatory response in myocardial injury, repair, and remodelling
Frangogiannis, N. G. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.28 · Cited by 1,738
Ridker, P. M. (2016) · Circulation Research · doi:10.1161/circresaha.115.306656 · Cited by 1,002
Interleukin-18 and IL-18 Binding Protein
Dinarello, C. A., Novick, D., Kim, S., & Kaplanski, G. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00289 · Cited by 938
“There are also preclinical studies demonstrating that blockade of IL-1β is effective (59, 60) and clinical trials using anakinra have revealed that blockade of IL-1 is effective in reducing post infarction remodeling (61, 62) as well as increased exercise tolerance (63).”
Self-citationOng, S.-B., Hernández-Reséndiz, S., Crespo-Avilan, G. E., Mukhametshina, R. T., Kwek, X.-Y., Cabrera-Fuentes, H. A., & Hausenloy, D. J. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.01.001 · Cited by 918
Metadata
- Authors
- Abbate, A., Van Tassell, B. W., Biondi-Zoccai, G., Kontos, M. C., Grizzard, J. D., Spillman, D. W., Oddi, C., Roberts, C. S., Melchior, R. D., Mueller, G. H., Abouzaki, N. A., Rengel, L. R., Varma, A., Gambill, M. L., Falcao, R. A., Voelkel, N. F., Dinarello, C. A., & Vetrovec, G. W.
- Venue
- The American Journal of Cardiology
- Publisher
- Elsevier BV
- Published
- 2013-05
- Volume
- 111
- Issue
- 10
- Pages
- 1394-1400
- ISSN
- 0002-9149 (ISSN-L)
- OpenAlex
- W2032049229
- Cited by
- 393
- References
- 39
- FWCI
- 19.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.